Abstract
Asthma is an allergic disease that affects approximately 300 million people worldwide. Two of its phenotypes routinely assessed at the clinic include airway hyperresponsiveness and IgE production. They can be measured in a non-invasive manner and have been used for genetic studies.
The genetic complexity of asthma and its phenotypes makes it difficult to map their genetic contributors. Human studies require large sample sizes and proper segregation of the population to control for potential confounding factors. As an alternative, asthma genetics can be studied in mice due to the high degree of homology in the genome and immune response between mice and humans. The variety of mouse strains and allergic asthma protocols allow to study different aspects of the disease while controlling for the genetic background. Studying the genetic basis of asthma phenotypes has helped gain a better understanding of the disease mechanism. Candidate genes identified from genetic studies have served as targets for the development of new and specialized treatments. New treatments are high in demand as the symptoms of a large number of asthmatics are not properly controlled with the existing treatment guidelines involving corticosteroids, β2-adrenoreceptor agonists, and anti-leukotrienes or leukotriene modifiers. Promising findings have been obtained from studies exploring new treatments targeting specific immune cell mediators, which were identified as candidates in genetic studies, and cell adhesion molecules. In addition to targeting members of the Th1/Th2 inflammatory profile, mediators of the omega-3 fatty acid pathway are also emerging as novel targets of drug intervention for allergic asthma.Keywords: Allergic asthma, asthma genetics, treatments, mouse models, airway hyperresponsiveness, IgE.
Current Pharmaceutical Design
Title:Allergic Asthma: A Summary from Genetic Basis, Mouse Studies, to Diagnosis and Treatment
Volume: 22 Issue: 41
Author(s): Cynthia Kanagaratham and Danuta Radzioch
Affiliation:
Keywords: Allergic asthma, asthma genetics, treatments, mouse models, airway hyperresponsiveness, IgE.
Abstract: Asthma is an allergic disease that affects approximately 300 million people worldwide. Two of its phenotypes routinely assessed at the clinic include airway hyperresponsiveness and IgE production. They can be measured in a non-invasive manner and have been used for genetic studies.
The genetic complexity of asthma and its phenotypes makes it difficult to map their genetic contributors. Human studies require large sample sizes and proper segregation of the population to control for potential confounding factors. As an alternative, asthma genetics can be studied in mice due to the high degree of homology in the genome and immune response between mice and humans. The variety of mouse strains and allergic asthma protocols allow to study different aspects of the disease while controlling for the genetic background. Studying the genetic basis of asthma phenotypes has helped gain a better understanding of the disease mechanism. Candidate genes identified from genetic studies have served as targets for the development of new and specialized treatments. New treatments are high in demand as the symptoms of a large number of asthmatics are not properly controlled with the existing treatment guidelines involving corticosteroids, β2-adrenoreceptor agonists, and anti-leukotrienes or leukotriene modifiers. Promising findings have been obtained from studies exploring new treatments targeting specific immune cell mediators, which were identified as candidates in genetic studies, and cell adhesion molecules. In addition to targeting members of the Th1/Th2 inflammatory profile, mediators of the omega-3 fatty acid pathway are also emerging as novel targets of drug intervention for allergic asthma.Export Options
About this article
Cite this article as:
Kanagaratham Cynthia and Radzioch Danuta, Allergic Asthma: A Summary from Genetic Basis, Mouse Studies, to Diagnosis and Treatment, Current Pharmaceutical Design 2016; 22 (41) . https://dx.doi.org/10.2174/1381612822666160829141708
DOI https://dx.doi.org/10.2174/1381612822666160829141708 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Addiction Liability of Pharmacotherapeutic Interventions in Obesity
Current Pharmaceutical Design The Myometrium in Pregnant Women with Obesity
Current Vascular Pharmacology Muscle Atrophy Classification: The Need for a Pathway-Driven Approach
Current Pharmaceutical Design Role of the Transforming-Growth-Factor-β1 Gene in Late-Onset Alzheimer’s Disease: Implications for the Treatment
Current Genomics Neuropathic Pain and Lung Delivery of Nanoparticulate Drugs: An Emerging Novel Therapeutic Strategy
CNS & Neurological Disorders - Drug Targets Noradrenergic System in Down Syndrome and Alzheimer’s Disease A Target for Therapy
Current Alzheimer Research Indications for Non-Invasive Ventilation in Respiratory Failure
Reviews on Recent Clinical Trials Histaminergic Control of Sleep-Wake Cycles: Recent Therapeutic Advances for Sleep and Wake Disorders
CNS & Neurological Disorders - Drug Targets Acne in the Adult
Mini-Reviews in Medicinal Chemistry Preliminary Functional Characterization, Cloning and Primary Sequence of Fastuosain, a Cysteine Peptidase Isolated from Fruits of Bromelia fastuosa
Protein & Peptide Letters Dietary Salt and Disease Prevention: A Global Perspective
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents New Prospects for Drug Discovery from Structural Studies of Rhodopsin
Current Pharmaceutical Design Clinical and Pharmacological Aspects of Immunoprophylaxis for Respiratory Syncytial Virus Infection in High-Risk Infants
Current Drug Metabolism Apoptosis in the Homeostasis of the Immune System and in Human Immune Mediated Diseases
Current Pharmaceutical Design Interleukin-4, Interleukin-13, Signal Transducer and Activator of Transcription Factor 6, and Allergic Asthma
Current Molecular Medicine Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued) Meet Our Editorial Board Member
Current Respiratory Medicine Reviews Progress in Research of K<sub>V</sub>1.1 and K<sub>V</sub>1.3 Channels as Therapeutic Targets
Current Topics in Medicinal Chemistry Sundowning Syndrome: A Possible Marker of Frailty in Alzheimer’s Disease?
CNS & Neurological Disorders - Drug Targets Macrolide Therapy Targets a Specific Phenotype in Respiratory Medicine: From Clinical Experience to Basic Science and Back
Inflammation & Allergy - Drug Targets (Discontinued)